Adjuvant chemotherapy is not for everyone

Breast Cancer Research and Treatment

Volumn 123, Issue 1, 2010, Pages 159-162

  Henderson, I Craig ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PACLITAXEL; TAXANE DERIVATIVE; PROGESTERONE RECEPTOR;

ADJUVANT THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; HUMAN; MASTECTOMY; MULTIPLE CYCLE TREATMENT; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; BIOSYNTHESIS; BREAST NEOPLASMS; FEMALE; GENETICS; META ANALYSIS (TOPIC);

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; META-ANALYSIS AS TOPIC; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 77955769132     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-0964-2     Document Type: Note

References (21)

1. IC Henderson GP Canellos 1980 Cancer of the breast: the past decade N Engl J Med 302 17 30 1:STN:280:DyaL3c%2Fnslyrug%3D%3D 6985698 78-90
2. DM Barnes IS Fentiman RR Millis RD Rubens 1989 Who needs steroid receptor assays? Lancet 1 1126 1127 10.1016/S0140-6736(89)92395-7 1:STN:280: DyaL1M3jslGqsQ%3D%3D 2566061
3. M Baum 1989 Who needs steroid receptor assays? Lancet 2 282 10.1016/S0140-6736(89)90475-3 1:STN:280:DyaL1MzjtVShsA%3D%3D 2569095
4. ME Lippman JC Allegra EB Thompson,, et al. 1978 The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer N Engl J Med 298 1223 1228 1:STN:280:DyaE1c7nslSnsw%3D%3D 651963
5. DJT Webster DG Bronn JP Minton 1978 Estrogen receptors and response of breast cancer to chemotherapy N Engl J Med 299 604
6. B Samal A Singhakowinta SC Brooks VK Vaitkevicius 1978 Estrogen receptors and response of breast cancer to chemotherapy N Engl J Med 299 604
7. EM Greenspan 1978 Estrogen receptors and response of breast cancer to chemotherapy N Engl J Med 299 604
8. SS Legha GR Blumenschien AU Buzdar GN Hortobagyi 1979 Hormone receptors in breast cancer and response to chemotherapy N Engl J Med 300 1053 1:STN:280:DyaE1M7ls1KlsA%3D%3D 431601
9. Early Breast Cancer Trials Collaborative Group 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687 1717 10.1016/S0140-6736(05)66544-0 (Pubitemid 40719106)
10. DA Berry C Cirrincione IC Henderson,, et al. 2006 Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer JAMA 295 1658 1667 10.1001/jama.295.14.1658 1:CAS:528: DC%2BD28XjsVeqs7k%3D 16609087
11. HB Muss AD Thor DA Berry,, et al. 1994 c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer N Engl J Med 330 1260 1266 10.1056/NEJM199405053301802 1:STN:280:DyaK2c7psFensQ%3D%3D 7908410 (Pubitemid 24129958)
12. B Dhesy-Thind KI Pritchard H Messersmith F O'Malley L Elavathil M Trudeau 2008 HER2/neu in systemic therapy for women with breast cancer: a systematic review Breast Cancer Res Treat 109 209 229 10.1007/s10549-007-9656-y 1:CAS:528:DC%2BD1cXlsV2ntrs%3D 17636396 (Pubitemid 351644854)
13. DF Hayes AD Thor LG Dressler,, et al. 2007 HER2 and response to paclitaxel in node-positive breast cancer N Engl J Med 357 1496 1506 10.1056/NEJMoa071167 1:CAS:528:DC%2BD2sXhtFKmurrO 17928597 (Pubitemid 47572635)
14. M Martin A Rodriguez-Lescure A Ruiz,, et al. 2008 Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer J Natl Cancer Inst 100 805 814 10.1093/jnci/djn151 1:CAS:528:DC%2BD1cXmvFWksr0%3D 18505968 (Pubitemid 351809668)
15. M Martin T Pienkowski J Mackey,, et al. 2005 Adjuvant docetaxel for node-positive breast cancer N Engl J Med 352 2302 2313 10.1056/NEJMoa043681 1:CAS:528:DC%2BD2MXksl2lt7c%3D 15930421 (Pubitemid 40740554)
16. P Ellis P Barrett-Lee L Johnson,, et al. 2009 Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial Lancet 373 1681 1692 10.1016/S0140-6736(09)60740-6 1:CAS:528:DC%2BD1MXmtVWjtL0%3D 19447249
17. P Francis J Crown A Di Leo,, et al. 2008 Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial J Natl Cancer Inst 100 121 133 10.1093/jnci/djm287 1:CAS:528:DC%2BD1cXivVOnsr8%3D 18182617 (Pubitemid 351480565)
18. JC Chang EC Wooten A Tsimelzon,, et al. 2003 Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer Lancet 362 362 369 10.1016/S0140-6736(03)14023-8 1:CAS:528: DC%2BD3sXlvFGnsLo%3D 12907009 (Pubitemid 36957839)
19. Martin M, Rodríguez-Lescure A, Ruiz A, et al (2010) Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Res Treat. doi: 10.1007/s10549-009-0663-z
20. Berry DA, Thor AD, Jewell SD, et al (2009) Benefits of adding paclitaxel to adjuvant doxorubicin/cyclophosphamide depending on HER2 & ER status: analysis of tumor tissue microarrays and immunohistochemistry in CALGB 9344 (Intergroup 0148). In: 32nd annual San Antonio Breast Cancer Symposium, San Antonio, TX, USA, p 606
21. IC Henderson DA Berry GD Demetri,, et al. 2003 Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer J Clin Oncol 21 976 983 10.1200/JCO.2003.02.063 1:CAS:528: DC%2BD2cXpsVGqs7c%3D 12637460 (Pubitemid 46594124)